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Background/aim: This study performed typing of chronic obstructive pulmonary disease (COPD) using high-resolution computed
tomography (HRCT) to determine the association with smoking, matrix metalloproteinases, and common comorbidities.
Materials and methods: The study enrolled 94 hospitalized patients. Participants were divided into a group of 69 current and former
smokers (group A) and a group of 25 that had never smoked (group B). Patients were also divided into 3 categories according to the
degree of emphysema and bronchial wall thickness using HRCT to determine the association with levels of matrix metalloproteinase 9
(MMP-9) and TIMP-1, as well as associated comorbidities. These three categories were: type A - no or mild emphysema, with or without
bronchial wall thickening; type E - emphysema without bronchial wall thickening; and type M - both emphysema and bronchial wall
thickening.
Results: The low attenuation area (LAA) scores in group A patients were higher than those in group B (t = 2.86, P < 0.01); correlation
analysis showed that smoking was associated with a decline of the forced expiratory volume in 1 s and forced vital capacity ratio (FEV1/
FVC%) and higher LAA scores in patients with COPD (F = 4.46, F = 8.20, P < 0.05). The levels of MMP-9 in group A were higher
than those in group B (t = 3.65, P < 0.01). Among COPD patients with more than 3 comorbidities, there were statistically significant
differences in both the smoking group and the nonsmoking group (chi-square = 12.08, P < 0.01). When compared to type A patients,
who had coincident cardiovascular diseases in the smoking group, patients of type M and E showed statistically significant differences
(F = 2.42 and 2.12, P < 0.05).
Conclusion: Emphysema was more severe in smokers. Metalloproteinase levels in smokers were higher than those in nonsmokers.
Moreover, comorbidities were more severe in smokers.
Key words: Smoking, COPD, high-resolution computed tomography, emphysema, chronic bronchitis, metalloproteinase, comorbidities

1. Introduction
Pulmonary function testing plays an important role in the
diagnosis and evaluation of chronic obstructive pulmonary
disease (COPD). However, as the severity of COPD cannot be
assessed using pulmonary function alone, it is also necessary
to evaluate airway inflammation, the time of onset, the extent
of lung destruction, pathological changes, and associated
comorbidities (1,2). Neutrophils, macrophages, lymphocytes,
and inflammatory mediators are involved in airway
inflammation and structural damage. Metalloproteinases also
play a key role in airway and parenchymal structural damage
and airflow limitation in COPD (3–5). High-resolution
computed tomography (HRCT) can be used to assess the
destruction of lung structure in COPD (6) and the findings
are associated with pathological changes in COPD (7,8). In

addition, a variety of comorbidities affect the quality of life
in patients with COPD. Smoking and other factors, such as
biofuel exposure, are important causes of COPD (9,10). This
study examined the use of CT to classify airway inflammation
and the association with matrix metalloproteinases and
their inhibitors, as well as common comorbidities in COPD
patients with and without a smoking history. The clinical
features of COPD patients were comprehensively assessed to
establish a theoretical basis for individualized treatment of
COPD.
2. Materials and methods
2.1. Subjects
The study was conducted in the Petroleum Clinical
Medical College of Hebei Medical University and enrolled
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94 patients hospitalized between January 2016 and
December 2016. There were 56 males and 38 females, with
ages ranging from 48 to 87 years old. The average age was
71 ± 9 years old. Participants were divided into a group
of 69 (73.4%) current and former smokers (group A)
and a group of 25 that had never smoked (26.6%) (group
B). The diagnosis of COPD was based on criteria in the
literature (7–9). The Petroleum Clinical Medical College
of Hebei Medical University approved the study, and all
patients provided signed informed consent. All patients
had pulmonary function testing and chest HRCT. Routine
blood testing was performed on the day after admission,
and levels of matrix metalloproteinases and their inhibitors
were determined.
2.2. Measures of emphysema by using HRCT
Subjective, semiquantitative measurement of emphysema
was made by visual assessment of HRCT images, using
Syngo CT SOMATOM Definition Flash Pulmo 3D imageprocessing software (Siemens AG, Germany), with a low
attenuation area (LAA) defined as less than –960 HU.
The following three anatomical layers were evaluated: 1)
close to the upper margin for 1 cm of the aortic arch; 2)
horizontal margin for 1 cm of carina; 3) upper margin for
3 cm of the right diaphragm, as shown in Figure 1. The
LAA was determined for three lung fields, based on the
percentage of each layer in each lung field. The LAA score
was calculated for each layer as previously described (11):
0 points for LAA of <5%, 1 point for 5% ≤ LAA < 25%,
2 points for 25% ≤ LAA < 50%, 3 points for 50% ≤ LAA
< 75%, and 4 points for LAA of >75%. The grade was
determined by the total score for the three layers: grade 0
for 0 points, grade 1 for 1–3 points, grade 2 for 4–6 points,
grade 3 for 7–9 points, and grade 4 for 10–12 points.
2.3. Measurement of bronchial wall
Enlarged targeted scanning images of the right upper lobe
were used to rebuild the apical segmental bronchus with
multiplanar reformation, after determining the crosssection perpendicular to the fifth bronchial lumen, as
confirmed by two experienced radiologists. Bronchial wall

thickness (T) and pulmonary artery (PA) diameter in the
same layer were measured using image magnification, and
the ratio of the airway wall thickness to the pulmonary
artery diameter (T/PA) was calculated. Classification
of bronchial wall thickness in 3 layers was performed as
previously described (12): grade 0 for T/PA of <30%, grade
1 for 30% ≤ T/PA < 50%, and grade 2 for T/PA of ≥50%.
2.4. HRCT classification
The modified Kitaguchi method (11) was used for
evaluation of emphysema and bronchial wall thickness,
and three imaging types were defined, as follows: 1) type A:
no or mild emphysema (LAA ≤ Grade 1), with or without
bronchial wall thickening; 2) type E: emphysema (LAA ≥
Grade 2) without bronchial wall thickening; and 3) type
M: both emphysema (LAA ≥ Grade 2) and bronchial wall
thickening (LAA ≥ Grade 1).
2.5. Statistical analysis
Statistical analysis was performed using SPSS 19.0 (IBM
Corp., Armonk, NY, USA) and data were analyzed using
the t-test for comparisons between two groups. Analysis
of variance (ANOVA) was used for comparisons among
multiple groups. Enumeration data were analyzed using
the chi-square test. Correlation analysis was performed
using Pearson’s chi-square, and P < 0.05 was considered a
statistically significant difference.
3. Results
3.1. Chest CT types
The chest CT types of smokers belonging to group A are
shown in Table 1 and Figure 1. In this study, we found that
the sample size of group B was significantly less than that
of group A. Thus, we verified that each parameter between
the two groups was not a statistically significant difference
(F = 0.283, 0.660, 0.247, 0.714, 0.422, 0.686, 0.140; P > 0.05)
by using the homogeneity of variance test. The sample
size of the two groups was found to be appropriate. The
LAA score (9.38 ± 4.62) in group A showed a statistically
significant difference (t = 2.86, P < 0.01) compared with

Figure 1. A) The layer close to the upper margin for 1 cm of arcus aortae; B) horizontal margin for 1 cm of carina; C) upper margin for
3 cm of the right diaphragm, pink-purple part is the low attenuation area (LAA).
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Table 1. The comparison of LAA score and T/PA of subtypes between the smoking patients and
nonsmoking patients (mean ± SD).
Group
A

B

a

Subtype

Case

LAA score

T/PA

F

P

A

11

4.73 ± 4.61

E

13

9.92 ± 4.57

M

45

10.36 ± 3.99a

0.25 ± 0.04

121.27

<0.05

0.41 ± 0.08a

66.34

<0.05

0.32 ± 0.06

0.35 ± 0.07
a

A

9

2.56 ± 0.53

E

6

9.83 ± 4.26b

0.26 ± 0.03

193.73

<0.05

M

10

7.60 ± 4.27

0.40 ± 0.06

24.96

<0.05

b

b

Compared with type A, t =2.42–4.07, P < 0.05; b compared with type A, t = 2.82–5.16, P < 0.05.

that in group B (6.32 ± 4.45). One-way ANOVA showed
that the LAA score in COPD patients was correlated with
smoking, and it was considered to indicate a statistically
significant difference (F = 8.20, P < 0.01).
In group A, the number of type M patients (45, 47.95%)
was significantly higher than that of type A (11, 11.7%)
and type E (13, 13.8%) patients. Compared with type
A, the LAA score of type E and type M patients showed
a statistically significant difference (F = 4.07, F = 2.76, P
< 0.01); however, the LAA score showed no significant
difference between type E and type M (t = 0.33, P > 0.05).
In group B, compared with type A (9 cases, 9%), the LAA
score of type E and type M patients showed a statistically
significant difference (F = 3.51, F = 5.16, P < 0.01), and the
LAA score showed no significant difference between type
E and type M patients (t = 1.01, P > 0.05).
A comparison of T/PA in group A (0.37 ± 0.10) with
that in group B showed no statistically significant difference
(t = 1.51, P > 0.05), but a comparison of T/PA in type M
and type A showed a statistically significant difference (t =
2.42, t = 2.82, P < 0.05) both in group A and group B.
3.2. Association of inflammatory markers with lung
function
The neutrophil percentage (76.78 ± 10.80%) and
lymphocyte percentage (15.73 ± 9.18%) in group A
compared with that in group B (N%: 67.41 ± 12.65%, T%:
22.51 ± 12.08%) showed a statistically significant difference
(t = 3.55 and 2.90, P < 0.01), as shown in Figure 2. There
were no differences (P > 0.05) in the level of procalcitonin,
neutrophil percentage (N%), and lymphocyte percentage
(T%) among types A, E, and M, both in group A and
group B. There were no differences (P > 0.05) in the forced
expiratory volume in 1 s/forced vital capacity ratio (FEV1/
FVC%), percent of forced vital capacity (FEV1%), mean
maximal midexpiratory flow (MMEF) 25%–75%, and the
residual volume to total lung capacity ratio (RV/TLC%)
among types A, E, and M. However, the FEV1/FVC% in

Figure 2. The neutrophil percentage and the lymphocyte
percentage in two groups.

group B (59.80 ± 9.37%) was higher than that in group
A (55.07 ± 9.67%), showing a statistically significant
difference (t = 2.11, P < 0.05). ANOVA revealed that the
decline of FEV1/FVC% was correlated with smoking,
showing a statistically significant difference (F = 4.46, P
< 0.05). There were no differences (P > 0.05) in the FEV1/
FVC%, FEV1%, MMEF 25%–75%, and RV/TLC% among
types A, E, and M, both in group A and group B.
3.3. Levels of matrix metalloproteinase 9 (MMP-9) and
tissue inhibitor of metalloproteinase-1 (TIMP-1), and
the ratio of MMP-9/TIMP-1
The levels of MMP-9 and TIMP-1 and the ratio of MMP-9/
TIMP-1 are shown in Table 2. The levels of MMP-9 in the
three CT subtypes in group A and B were higher than those
in healthy subjects (P < 0.05). The differences in TIMP-1
and MMP-9/TIMP-1 between group A and the healthy
subjects were statistically significant (P < 0.05). The ratio
of MMP-9/TIMP-1 in the M and E subtypes of group B
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Table 2. Comparison of MMP-9 and TIMP-1 in subtypes (mean ± SD).
Group
A

B

a

MMP-9 (ng/L)

TIMP-1 (ng/L)

MMP-9/TIMP-1

P

Type A (11)

135.62 ± 9.94

128.55 ± 25.78

0.84 ± 0.18

<0.05

Type E (13)

133.69 ± 10.17

120.25 ± 10.18

0.91 ± 0.17

<0.05

Type M (45)

128.31 ± 7.78

120.07 ± 17.76

0.86 ± 0.10

>0.05

Type A (9)

122.93 ± 8.01

150.03 ± 87.80

0.84 ± 0.11

>0.05

Type E (6)

123.31 ± 8.15

114.21 ± 10.63

0.86 ± 0.05

>0.05

Type M (10)

123.44 ± 5.94

123.01 ± 22.93

0.86 ± 0.11

>0.05

a
a

Compared with type M, t = 2.05–2.65, P < 0.05.

was significantly different from that in healthy subjects (P
< 0.05). There was a significant difference between group
A and group B (P < 0.05).
In COPD patients, the level of MMP-9 (130.49 ± 9.01
ng/L) was significantly higher than that in group B (123.21
± 6.96 ng/L), showing a statistically significant difference
(t = 3.65, P < 0.01). However, there was no difference in
TIMP-1 and the ratio of MMP-9/TIMP-1.
In group A, the level of MMP-9 (128.31 ± 7.77 ng/L)
in type M patients was significantly lower than that in
type A (135.62 ± 9.94 ng/L) and E (133.69 ± 10.17 ng/L),
showing a statistically significant difference (t = 2.05, 2.65,
P < 0.05). There was no difference in TIMP-1 and the ratio
of MMP-9/TIMP-1 among types A, E, and M. In group B,
there was no difference in MMP-9, TIMP-1, and the ratio
of MMP-9/TIMP-1 among types A, E, and M. The levels
of MMP-9 and TIMP-1 showed a significantly negative
correlation with FEV1, with statistical significance (F =
27.11 and 91.62, P < 0.05).
3.4. Comorbidities
Among the 94 patients, 65 (69.1%) had cardiovascular
disease and 29 (30.9%) did not have cardiovascular disease,
but there were no differences among types A, E and M (P >
0.05). There were no differences in CT subtypes between 25
patients with respiratory failure and 69 without respiratory
failure. There were no differences in CT subtypes between
55 patients with fewer than 3 comorbidities and 39 with
more than 3 comorbidities.
There were no significant differences between group
A and group B in terms of combined respiratory failure
and cardiovascular disease (P > 0.05). Among patients
with combined cardiovascular disease, the differences
between types M and E and type A were statistically
significant (F = 2.42 and 2.12, P < 0.05). In patients
with more than 3 comorbidities, there were statistically
significant differences in subtypes between group A and
group B (chi-square = 12.08, P < 0.01). In group A, there
were statistically significant differences (t = 2.59, P < 0.05)
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between type M and type A in patients with more than
three comorbidities.
The associations of MMP-9 with comorbidities are
shown in Table 3. In group A, MMP-9 levels in those
with combined cardiovascular disease and 3 or more
comorbidities showed statistically significant differences
compared to those without cardiovascular disease and fewer
than 3 comorbidities (t = 3.07 and 5.69, P < 0.01). MMP9 levels in type M patients showed statistically significant
differences compared to levels in type A and E (F = 2.65
and 2.05, P < 0.05). In group B, there were statistically
significant differences (t = 2.54, P < 0.05) in MMP-9 levels
between patients with and without cardiovascular disease.
There were no significant differences in MMP-9, TIMP-1,
and the ratio of MMP-9/TIMP-1 according to the three CT
types.
4. Discussion
COPD is a chronic disease with high morbidity and
mortality rates. Smoking is the most important risk factor
for COPD (13,14). Smith et al. (6) showed that smoking
patients demonstrated emphysema subtypes on HRCT, and
that smoking was correlated with centrilobular emphysema
and panlobular emphysema, but had no correlation with
paraseptal emphysema. This study aimed to determine
whether there were differences in lung structure, airway
inflammation, and airflow limitations according to
smoking status and other risk factors for COPD, to
provide a theoretical basis for individual treatment. The
Kitaguchi method was used to evaluate emphysema and
small airway thickness. The results showed that the LAA
score for emphysema in smokers was significantly higher
than that in nonsmokers, and that the LAA score was
significantly correlated with smoking. In addition, airflow
limitation was an important feature in COPD. The study
found that the FEV1/FVC% in nonsmoking patients was
better than the FEV1/FVC% in smoking patients, and that
FEV1/FVC% was negatively associated with smoking,
with restriction being a more severe contributor to COPD
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Table 3. Comparison of two groups of metalloproteinases and their inhibitors in comorbidities (mean ± SD).

Comorbidities

Group A
MMP-9

Group B
TIMP-1

MMP-9/TIMP-1 MMP-9

TIMP-1

MMP-9/TIMP-1

P

Respiratory failure
Yes

128.99 ± 8.52

121.13 ± 13.61

0.88 ± 0.13

123.97 ± 5.66

119.17 ± 9.44

0.88 ± 0.06

No

130.41 ± 9.49

120.64 ± 19.83

0.86 ± 0.13

123.09 ± 7.29

132.81 ± 9.97

0.85 ± 0.10

Yes

132.06 ± 8.93a 120.99 ± 18.30

0.89 ± 0.13

125.62 ± 7.35a 132.70 ± 63.49

0.85 ± 0.11

No

125.26 ± 8.02

120.32 ± 17.94

0.87 ± 0.14

118.97 ± 3.52

126.93 ± 38.99

0.86 ± 0.07

>3

135.24 ± 8.17b 120.20 ± 18.71

0.88 ± 0.13

128.04 ± 2.99

199.65 ± 107.86 0.82 ± 0.18

≤3

124.99 ± 7.09

0.86 ± 0.13

122.31 ± 7.16

117.47 ± 27.59

>0.05

Cardiovascular disease
<0.05

Comorbidities
121.35 ± 17.68

>0.05

0.86 ± 0.08

Hospitalized

a

>1

131.04 ± 9.11

117.92 ± 19.19

0.89 ± 0.13

125.48 ± 6.10

114.86 ± 13.55

0.87 ± 0.06

≤1

128.97 ± 9.23

123.50 ± 16.74

0.86 ± 0.13

121.73 ± 7.29

141.14 ± 69.19

0.84 ± 0.12

>0.05

Compared with group “No”, t = 2.54–5.69, P < 0.05; b compared with group ≤3, P < 0.05.

compared with other causative factors. Based on CT
subtypes analysis, LAA scores of types M and E, whose
main manifestation was emphysema both in the smoking
and nonsmoking groups, were significantly higher than
those in group A in the nonsmoking group; moreover,
the more severe the degree of emphysema, the more
significant the decline in athletic ability and the more
significant the clinical symptoms (6,15). The present study
showed that patients with type A had a milder condition
and better prognosis than those with type M and type E.
The pathology in COPD patients was mainly manifested
as small airway stenosis and alveolar abnormalities. The
results of this study showed that the airway wall thickness
in type M was greater than in type A in both the smoking
and nonsmoking groups; however, the small airway
wall in the smoking group was not more significantly
thickened than that in the nonsmoking group, indicating
that smoking is not the only reason for small airway wall
thickening, but may be correlated with abnormalities
in the airway smooth muscle, mucus secretion, airway
inflammation, and other factors.
The worsening of chronic airway inflammation
is the basis for COPD pathophysiology. In this study,
the percentages of neutrophils and lymphocytes in the
peripheral blood of smoking patients were significantly
higher than those in nonsmokers; Smith et al. (6) and
Saetta et al. (16) showed that centrilobular emphysema
in smoking patients was most common, especially in
the right upper lung. Compared with panlobular and
paraseptal emphysema, the leukocytes in peripheral blood

with centrilobular emphysema were more significantly
increased, indicating that smoking was an important
factor in the worsening of airway inflammation in
centrilobular emphysema. Shin et al. (17) found that
melatonin effectively inhibited airway neutrophils induced
by smoking and reduced airway mucus secretion in a
mouse COPD model; thus, melatonin may become a new
drug for treatment of COPD.
Other than chronic inflammation, airway remodeling
is also an important pathological change in COPD.
MMP-9 is involved in airway and lung reconstruction
through the degradation of the extracellular matrix and
cell membranes; TIMP-1 is an inhibitor of MMP-9, and
imbalance both in MMP-9 and TIMP-1 led to airway
and lung reconstruction (18). In COPD patients, MMP-9
levels in the smoking and nonsmoking groups were higher
than those in a healthy group, indicating that MMP-9 is
involved in the pathogenesis of COPD. MMP-9 levels in
the smoking group were higher than in the nonsmoking
group, and airway and lung reconstruction and airflow
limitation were greater in smoking patients. In smoking
patients, analysis showed that MMP-9 and TIMP-1 were
negatively correlated with FEV1, consistent with reports
by Kwiatkowska et al. and Linder et al. (19,20).
Multiple studies (21–24) reported that patients with
cardiovascular disease, diabetes, depression, cancer,
and other diseases can show accelerated progression
of COPD, and that an increase of C-reactive protein,
interleukin-6, interleukin-8, and other markers can also
accelerate the process of COPD. The results of this study
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indicated that in COPD patients with more than three
comorbidities, the status of the smoking group was not
more severe than that of the nonsmoking group, and that
according to CT types, the status of type M patients with
more than three comorbidities was more severe than that
of type A patients. There were no differences among the
subgroups in the nonsmoking group, indicating that the
inflammatory mediators produced by harmful substances in
the smoke also aggravate the development of comorbidities
in the circulation. Other studies (24,25) showed that in
COPD patients with moderate and severe cardiovascular
and metabolic diseases, a variety of inflammatory mediators
exist in circulating blood. In the type M and type E smoking
groups, the status of COPD patients with cardiovascular
disease was more serious than that of type A patients; in
the nonsmoking group, there were no differences among
the three subtypes in COPD patients with cardiovascular
disease, indicating that although patients had quit smoking,

chronic inflammatory mediators persisted in the blood of
those with COPD and cardiovascular disease. In addition
to inflammatory mediators, MMP-9 was strongly linked
with cardiovascular diseases and multiple comorbidities in
the smoking group. These results suggest that smoking can
increase the level of circulating matrix metalloproteinases,
thereby aggravating the severity of COPD, cardiovascular
diseases, and multiple comorbidities.
In summary, smoking is the main factor that causes
significant aggravation of emphysema, as detected on
CT in COPD patients. Smoking results in the presence of
inflammatory mediators and metalloproteinases in the blood
and increases airway inflammation and airway remodeling,
thereby aggravating the progress of COPD. Currently, in the
COPD patients, classification of CT scan (types A, E, and
M) is also a significant tool for assessing the phenotypes in
COPD; meanwhile, it can provide the theoretical basis for
individualized treatment of COPD patients.
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